title: [Chronic myeloproliferative diseases and pregnancy].
abstract: OBJECTIVE
  To analyse the course of pregnancy in chronic myeloproliferative diseases (CMPD) with hyperthrombocytosis, primarily, essential thrombocytemia.
  
  
  METHODS
  The analysis of thrombogenic risk factors covered literature data and 8 cases observed by the authors.
  
  
  RESULTS
  Six pregnant women received long-term treatment with preparations of interferon-alpha in a dose 9-20 million IU a week (both before and during pregnancy). Rapid reduction of hyperthrombocytosis (1100-4000 x 10(9) l) and the absence of a negative effect on development of the fetus were seen in all the cases. Normal delivery on week 37-39 was in 4 patients, spontaneous abortion on week 24 was provoked by a car accident. Three gravidas (gestational week 28, 33 and 34) are still under observation. Lupus anticoagulant or elevation of anticardiolipin antibodies level was detected in 4 of 8 patients, 2 patients had heterozygous mutation of methylentetrahydrofolatereductase genes and factor V (Leiden). These patients were given lannacher, faxiparine, folic acid and discrete plasmapheresis (in 2 cases).
  
  
  CONCLUSIONS
  Gravidas with hyperthrombocytosis, if not contraindicated, must be treated with aspirin and interferon-alpha preparations at any gestational term. Moreover, it is necessary to exclude additional most prevalent causes of thrombophilia for adequate prevention of thromboses.
authors.forename: N V
authors.initials: NV
authors.lastname: Tsvetaeva
authors.forename: N D
authors.initials: ND
authors.lastname: Khoroshko
authors.forename: M A
authors.initials: MA
authors.lastname: Sokolova
authors.forename: R V
authors.initials: RV
authors.lastname: Shmakov
authors.forename: E A
authors.initials: EA
authors.lastname: Semenova
authors.forename: O V
authors.initials: OV
authors.lastname: Lopukhin
authors.forename: E A
authors.initials: EA
authors.lastname: Romanova
authors.forename: A V
authors.initials: AV
authors.lastname: Sudarikov
authors.forename: S A
authors.initials: SA
authors.lastname: Vasil'ev
authors.forename: E B
authors.initials: EB
authors.lastname: Orel
authors.forename: E   A
authors.initials: E
authors.lastname: Rudakova
authors.forename: V L
authors.initials: VL
authors.lastname: Ivanova
authors.forename: L A
authors.initials: LA
authors.lastname: Serebrianaia
authors.forename: G T
authors.initials: GT
authors.lastname: Sedova
authors.forename: T E
authors.initials: TE
authors.lastname: Manakova
authors.forename: V V
authors.initials: VV
authors.lastname: Tutaeva
authors.forename: A A
authors.initials: AA
authors.lastname: Levina
authors.forename: Iu I
authors.initials: IuI
authors.lastname: Mamukova
mesh_terms: D000328:Adult; D002908:Chronic Disease; D005260:Female; D006801:Humans; D009196:Myeloproliferative Disorders / Q000453:epidemiology* / Q000276:immunology; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000453:epidemiology*; D013922:Thrombocytosis / Q000453:epidemiology; D019851:Thrombophilia / Q000453:epidemiology; D014841:von Willebrand Factor / Q000276:immunology
chemical_list: D014841:von Willebrand Factor